|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SENP7 |
Gene summary for SENP7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SENP7 | Gene ID | 57337 |
| Gene name | SUMO specific peptidase 7 | |
| Gene Alias | SENP7 | |
| Cytomap | 3q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | J3QT09 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57337 | SENP7 | LZE4T | Human | Esophagus | ESCC | 1.35e-08 | 2.69e-01 | 0.0811 |
| 57337 | SENP7 | LZE5T | Human | Esophagus | ESCC | 2.60e-06 | 2.41e-01 | 0.0514 |
| 57337 | SENP7 | LZE7T | Human | Esophagus | ESCC | 9.24e-03 | 1.00e-01 | 0.0667 |
| 57337 | SENP7 | LZE8T | Human | Esophagus | ESCC | 2.98e-04 | 1.28e-01 | 0.067 |
| 57337 | SENP7 | LZE20T | Human | Esophagus | ESCC | 5.43e-07 | 1.14e-01 | 0.0662 |
| 57337 | SENP7 | LZE22T | Human | Esophagus | ESCC | 8.65e-03 | 1.53e-01 | 0.068 |
| 57337 | SENP7 | LZE24T | Human | Esophagus | ESCC | 1.55e-24 | 4.56e-01 | 0.0596 |
| 57337 | SENP7 | P1T-E | Human | Esophagus | ESCC | 1.77e-07 | 2.20e-01 | 0.0875 |
| 57337 | SENP7 | P2T-E | Human | Esophagus | ESCC | 2.35e-07 | 8.67e-02 | 0.1177 |
| 57337 | SENP7 | P4T-E | Human | Esophagus | ESCC | 8.41e-12 | 1.64e-01 | 0.1323 |
| 57337 | SENP7 | P5T-E | Human | Esophagus | ESCC | 5.52e-08 | 1.07e-01 | 0.1327 |
| 57337 | SENP7 | P8T-E | Human | Esophagus | ESCC | 3.07e-22 | 3.41e-01 | 0.0889 |
| 57337 | SENP7 | P9T-E | Human | Esophagus | ESCC | 1.21e-13 | 1.82e-01 | 0.1131 |
| 57337 | SENP7 | P10T-E | Human | Esophagus | ESCC | 1.75e-25 | 3.66e-01 | 0.116 |
| 57337 | SENP7 | P11T-E | Human | Esophagus | ESCC | 8.42e-05 | 1.07e-01 | 0.1426 |
| 57337 | SENP7 | P12T-E | Human | Esophagus | ESCC | 1.06e-12 | 1.90e-01 | 0.1122 |
| 57337 | SENP7 | P15T-E | Human | Esophagus | ESCC | 4.75e-13 | 2.18e-01 | 0.1149 |
| 57337 | SENP7 | P16T-E | Human | Esophagus | ESCC | 2.32e-21 | 2.23e-01 | 0.1153 |
| 57337 | SENP7 | P17T-E | Human | Esophagus | ESCC | 1.27e-04 | 1.99e-01 | 0.1278 |
| 57337 | SENP7 | P19T-E | Human | Esophagus | ESCC | 1.04e-04 | 3.95e-01 | 0.1662 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
| GO:00182059 | Thyroid | PTC | peptidyl-lysine modification | 188/5968 | 376/18723 | 1.34e-13 | 7.09e-12 | 188 |
| GO:00706465 | Thyroid | PTC | protein modification by small protein removal | 71/5968 | 157/18723 | 3.03e-04 | 2.12e-03 | 71 |
| GO:001820516 | Thyroid | ATC | peptidyl-lysine modification | 193/6293 | 376/18723 | 6.92e-13 | 3.06e-11 | 193 |
| GO:007064613 | Thyroid | ATC | protein modification by small protein removal | 71/6293 | 157/18723 | 1.59e-03 | 7.99e-03 | 71 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SENP7 | SNV | Missense_Mutation | novel | c.2385N>A | p.Asp795Glu | p.D795E | Q9BQF6 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| SENP7 | SNV | Missense_Mutation | novel | c.2405N>C | p.His802Pro | p.H802P | Q9BQF6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SENP7 | SNV | Missense_Mutation | c.2941N>T | p.Pro981Ser | p.P981S | Q9BQF6 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SENP7 | SNV | Missense_Mutation | c.331C>G | p.Arg111Gly | p.R111G | Q9BQF6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD | |
| SENP7 | SNV | Missense_Mutation | novel | c.3009C>A | p.Phe1003Leu | p.F1003L | Q9BQF6 | protein_coding | deleterious(0) | benign(0.193) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| SENP7 | SNV | Missense_Mutation | rs765866688 | c.248N>A | p.Arg83Gln | p.R83Q | Q9BQF6 | protein_coding | tolerated(0.49) | benign(0.055) | TCGA-OL-A66L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SENP7 | SNV | Missense_Mutation | novel | c.175N>G | p.Leu59Val | p.L59V | Q9BQF6 | protein_coding | tolerated(0.39) | benign(0.001) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| SENP7 | SNV | Missense_Mutation | novel | c.1970N>T | p.Trp657Leu | p.W657L | Q9BQF6 | protein_coding | tolerated(0.62) | benign(0.052) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
| SENP7 | SNV | Missense_Mutation | c.3143N>A | p.Ser1048Asn | p.S1048N | Q9BQF6 | protein_coding | tolerated(0.06) | benign(0.025) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SENP7 | SNV | Missense_Mutation | c.2424N>G | p.Phe808Leu | p.F808L | Q9BQF6 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | DIHYDROXANTHOHUMOL | DIHYDROXANTHOHUMOL | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | TCMDC-124307 | CHEMBL546865 | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | 4-PHENYLAMINO-[1,2]NAPHTHOQUINONE | CHEMBL299853 | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | GNF-PF-5159 | CHEMBL1493528 | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | GNF-PF-4068 | CHEMBL584668 | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | 2-(4-NITROBENZYLSULFANYL)BENZOXAZOLE | CHEMBL412603 | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | GNF-PF-5151 | CHEMBL576208 | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | XANTHOANGELOL B | XANTHOANGELOL B | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | GNF-PF-992 | CHEMBL602561 | ||
| 57337 | SENP7 | ENZYME, DRUGGABLE GENOME, PROTEASE | DNDI1417156 | CHEMBL1504679 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |